PepGen Inc.
NASDAQ:PEPGBiotechnology
+$0.09 today
- Market cap
- $268.73M
- Beta
- 1.93
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$1.12
Volume 5.61M
Average 1.37M
PEPG EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
PepGen Inc.NASDAQ: PEPG
EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026
EPS (Diluted) remains negative
Q1 FY2026 EPS (Diluted) was -$0.42, compared with -$0.92 a year earlier. Trailing-twelve-month EPS (Diluted) was -$2.1.
Context
- EPS (Diluted) grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 6 analysts of -$1.11 (+47.5%) for the fiscal year ending Dec 2026, a step up from the +25.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.42+2.3% QoQ
- Last fiscal yearDec 2025
- -$2.12+25.6% YoY
- LTMMar 2026
- -$2.1+32.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +54.3% | +59.4% | +5.0 pp |
| 1 year | +25.6% | +47.5% | +21.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (2.12) USD
- Year-over-year change
- +25.6%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.12) | +25.6% |
| FY2024 | 2024-12-31 | (2.85) | +13.6% |
| FY2023 | 2023-12-31 | (3.30) | +25.3% |
| FY2022 | 2022-12-31 | (4.42) | -262.3% |
| FY2021 | 2021-12-31 | (1.22) | — |
EPS (Diluted) vs competitors
How PEPG compares with its peers on the latest reported figures
- Peers report in different currencies, so EPS (Diluted) is compared through growth and rates rather than absolute size.
- Its year-over-year change of +32.9% is the 3rd highest of 8, against a peer median of +11.3%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | -$0.67 USD | +35.6% | — | |
| LTM Mar 2026 | -$1.09 USD | +26.8% | — | |
| LTM Mar 2026 | -$1.19 USD | +6.4% | — | |
| LTM Mar 2026 | -$1.34 USD | +11.3% | — | |
| LTM Mar 2026 | -CHF 1.56 CHF | +9.3% | — | |
| LTM Mar 2026 | -$2.1 USD | +32.9% | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | -$2.36 USD | +41.7% | — |
| LTM Mar 2026 | -$6.6 USD | +3.9% | — | |
| Peer median (excluding PEPG) | — | +11.3% | — | |
Competitors are the stored peer set for PEPG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 1.18M | 1.51M | 1.4M |
| Gross Profit | 0 | 0 | (1.18M) | (1.51M) | (1.4M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 23.8M | 54.08M | 68.13M | 76.48M | 71.04M |
| Selling, General & Admin | 8.11M | 14.22M | 16.64M | 21.26M | 22.57M |
| Operating Expenses | 27.11M | 68.3M | 83.58M | 96.23M | 92.22M |
| Depreciation & Amortization | 178K | 493K | 1.18M | 1.51M | 1.4M |
| EBITDA | (27.1M) | (64.91M) | (77.37M) | (89.09M) | (88.21M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (27.11M) | (68.3M) | (84.77M) | (97.74M) | (93.61M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 2.79M | 6.4M | 7.14M | 4.02M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (172K) | 2.9M | 6.21M | 7.14M | 4.01M |
| Income Before Tax | (27.28M) | (65.4M) | (78.55M) | (90.6M) | (89.61M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 3.71M | 73K | (617K) | 49K |
| Net Income | (27.28M) | (69.1M) | (78.63M) | (89.98M) | (89.66M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.22) | (4.42) | (3.30) | (2.85) | (2.12) |
| EPS (Diluted) | (1.22) | (4.42) | (3.30) | (2.85) | (2.12) |
| Weighted Avg Shares | 22.39M | 15.64M | 23.8M | 31.58M | 42.22M |
| Weighted Avg Shares (Diluted) | 22.39M | 15.64M | 23.8M | 31.58M | 42.22M |
PepGen Inc.
NASDAQ:PEPG
Intrinsic Alpha fair value
Locked
Current Price
$3.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.